Loading...
XIDX
MRAT
Market cap8mUSD
Nov 12, Last price  
380.00IDR
Name

Mustika Ratu Tbk PT

Chart & Performance

D1W1MN
XIDX:MRAT chart
P/E
391.07
P/S
0.38
EPS
0.97
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
5.87%
Revenues
423.52b
+26.97%
307,804,260,789345,575,853,364369,366,074,883406,315,784,681458,197,338,824358,127,545,503434,747,101,600428,092,732,505344,361,345,265344,678,666,245300,572,751,733305,224,577,860318,408,499,475326,794,571,097285,177,566,612300,596,022,300333,562,950,000423,517,456,000
Net income
416m
P
22,290,067,70721,016,846,72024,418,796,93027,867,834,53230,751,407,882-6,700,373,0767,054,710,4111,045,990,311-5,549,465,678-1,319,951,850-2,257,132,420131,182,389-6,766,719,891358,126,93167,833,011,050-14,140,399,378-5,122,539,000415,889,000
CFO
16.30b
+207.51%
30,430,824,3322,437,835,0474,613,811,149702,986,21612,708,802,3428,221,522,955-22,679,473,943-8,272,888,090-16,529,433,188-10,355,155,394-5,750,378,923-6,529,917,745-18,174,189,911-6,645,903,88567,833,011,050-26,387,483,2245,301,482,00016,302,825,000
Dividend
Jul 11, 201316.525 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Indonesia, PT Mustika Ratu Tbk, along with its group of companies, is engaged in manufacturing, marketing, and distributing a diverse range of products. These include herbal and traditional beauty items, personal care essentials, jamu (Indonesian traditional herbal medicine), health beverages, and convenient ready-to-drink options. Their extensive product line features examples such as Herbamuno+ herbal supplements, facial cleansers, hydrating creams, body serums designed for toning, dual-purpose cleansers and toners, as well as various face mask preparations like creams and powders. Established in 1978, the firm maintains its main office in Jakarta, Indonesia, and functions as a subsidiary of PT Mustika Ratu Investama.
IPO date
Jul 27, 1995
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT